Saul Yanovich, M.D., a nationally known leader in blood and marrow transplantation, has been named clinical director of the Blood and Marrow Transplantation (BMT) Program at the University of Maryland Greenebaum Cancer Center. Dr. Yanovich, a hematologist and medical oncologist, is also on the faculty of the University of Maryland School of Medicine. He assumed his new position on April 1.
Dr. Yanovich comes to the University of Maryland from Georgetown University's Lombardi Cancer Center in Washington, D.C., where he served as medical director of the Bone Marrow Transplant Program since 2000. Previously, he directed the Bone Marrow Transplantation Unit at the Virginia Commonwealth University Medical Center in Richmond for more than seven years.
"Dr. Yanovich is highly regarded for his work in treating patients requiring blood and marrow transplantation. He has published extensively in the field and is very active in clinical research,” says Kevin J. Cullen, M.D., director of the University of Maryland Greenebaum Cancer Center and professor of medicine at the University of Maryland School of Medicine. “We are delighted that he is leading our BMT Program."
A native of Colombia, Dr. Yanovich graduated from Javeriana University School of Medicine in Bogota and completed his medical residency and a hematological fellowship at the University of Miami Hospitals. He also completed an oncology research fellowship at the Dana-Farber Cancer Institute in Boston.
"This new position represents an opportunity for professional growth for me," says Dr. Yanovich. "The University of Maryland Greenebaum Cancer Center already has a well-established blood and marrow transplantation program with a dedicated staff of physicians and health care professionals who provide the best possible care for patients. It also has an excellent translational research program, with a number of innovative clinical trials, bringing research advances from the laboratory to the bedside."
Dr. Yanovich says that he wants to expand the number of clinical trials available to patients, which would include establishing collaborations with national clinical research groups, and focus on patient care.
"We must always treat each patient as an individual," says Dr. Yanovich. “When our patients go home from the hospital, we want them to feel that we have done everything possible for them. This commitment to patient care is what sets the University of Maryland Greenebaum Cancer Center apart from many other institutions.”
Bone marrow and blood stem cell transplants are used to treat many cancers, including leukemia, Hodgkin’s disease, non-Hodgkin's lymphoma and multiple myeloma. The University of Maryland Greenebaum Cancer Center’s multidisciplinary BMT program provides autologous and allogeneic transplantation, an on-site stem cell collection facility, a sophisticated tissue typing laboratory and a self-contained inpatient unit for BMT patients.
# # #